Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial

Trial Profile

Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary) ; Imiquimod
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Acronyms VZIDST
  • Most Recent Events

    • 27 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.
    • 02 Dec 2015 Planned number of patients changed from 120 to 160, as reported by ClinicalTrials.gov.
    • 02 Dec 2015 Number of treatment arms changed from 4 to 5,treatment section revised with inclusion of one additional treatment arm "ID VZVv with imiquimod group".Also, planned number of subjects changed from 120 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top